Allergology International最新文献

{"title":"Cytokine profile of the stratum corneum in atopic dermatitis lesions differs between the face and the trunk","authors":"Makiko Kido-Nakahara ,&nbsp;Takahito Chiba ,&nbsp;Yuta Mizusawa ,&nbsp;Yuko Higashi ,&nbsp;Atsuko Ibusuki ,&nbsp;Satomi Igawa ,&nbsp;Yumi Murakami ,&nbsp;Hiroshi Matsunaka ,&nbsp;Yoko Kuba-Fuyuno ,&nbsp;Gaku Tsuji ,&nbsp;Takeshi Nakahara","doi":"10.1016/j.alit.2024.08.010","DOIUrl":"10.1016/j.alit.2024.08.010","url":null,"abstract":"<div><h3>Background</h3><div>Atopic dermatitis (AD) is a chronic inflammatory skin disease with intense pruritus. Dupilumab, an anti-IL-4 receptor alpha antibody, has been revealed to be highly effective against the symptoms of AD; however, dupilumab takes longer to improve facial dermatitis in some patients. We thus examined whether the cytokine profiles in AD lesions differ between different anatomical locations.</div></div><div><h3>Methods</h3><div>Stratum corneum was collected by tape stripping from lesions of the forehead and abdomen of 24 patients with moderate to severe AD and at the same anatomical locations of 14 control subjects. These samples were then used to determine the expression profiles of Th1, Th2, and Th17 cytokines/chemokines by multiplex assay and immunocytochemistry.</div></div><div><h3>Results</h3><div>We found that cytokines/chemokines in the stratum corneum differed in their expression between different anatomical areas in AD patients and also in healthy control subjects. The expression of Th1 and Th17 cytokines/chemokines such as IP-10, MIG, and IL-17 tended to be higher in the forehead than in the abdomen in the AD group. Regarding Th2 cytokines/chemokines, some (e.g., IL-13 and IL-33) were highly expressed in the abdomen, others (e.g., IL-4 and IL-31) were highly expressed in the forehead, and a third group (e.g., TARC and TSLP) did not differ significantly in their expression between the forehead and abdomen. These patterns of Th2 cytokines were almost identical in the stratum corneum of healthy individuals.</div></div><div><h3>Conclusions</h3><div>Differences in cytokine/chemokine profiles in the stratum corneum between different anatomical areas might affect the responsiveness to AD treatment.</div></div>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"74 2","pages":"Pages 222-232"},"PeriodicalIF":6.2,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142330516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent progress in allergen immunotherapy","authors":"Takumi Takizawa (Associate Editor, Allergology International)","doi":"10.1016/j.alit.2024.09.001","DOIUrl":"10.1016/j.alit.2024.09.001","url":null,"abstract":"","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"73 4","pages":"Pages 485-486"},"PeriodicalIF":6.2,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1323893024000911/pdfft?md5=93b807366da850a1f138676c7ba3f346&pid=1-s2.0-S1323893024000911-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142274690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current perspective on allergen immunotherapy for food allergies","authors":"Sakura Sato,&nbsp;Ken-ichi Nagakura,&nbsp;Noriyuki Yanagida,&nbsp;Motohiro Ebisawa","doi":"10.1016/j.alit.2024.08.002","DOIUrl":"10.1016/j.alit.2024.08.002","url":null,"abstract":"<div><p>Food allergies are an increasing global problem and societal issue. In addition to the potential for severe allergic reactions from accidental ingestion, food allergies impose a significant burden on the quality of life, nutrition, cost of living, and social activities of both those afflicted and their caregivers. Strict avoidance of allergens and use of emergency medications to treat allergic reactions are the traditional management and treatment strategies; however, significant progress has been made in recent years toward better treatment of food allergies. Many clinical trials on food allergen immunotherapy (oral, epicutaneous, and sublingual) have revealed its efficacy in increasing reaction thresholds and desensitization. These positive results led to the first FDA approval of peanut oral immunotherapy (OIT). However, safer and more effective approaches are required, and adjunct treatments and allergen modifications are being considered. More than 100 facilities in Japan conduct OIT, and numerous studies on it have been reported. Unlike in Europe and the US, stepwise oral food challenges with dietary guidance are conducted separately from the OIT. This review describes the current perspectives on allergen immunotherapy for the treatment of food allergies, focusing on evidence from Japan.</p></div>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"73 4","pages":"Pages 501-514"},"PeriodicalIF":6.2,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1323893024000832/pdfft?md5=0bbeb17d1e3ef9df5f540e4dabd7a391&pid=1-s2.0-S1323893024000832-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142113815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From the genesis to the present: The evolution of sublingual immunotherapy for cedar pollinosis","authors":"Minoru Gotoh ,&nbsp;Osamu Kaminuma ,&nbsp;Kimihiro Okubo","doi":"10.1016/j.alit.2024.07.001","DOIUrl":"10.1016/j.alit.2024.07.001","url":null,"abstract":"<div><p>In 2004, we started the initial attempt to evaluate the efficacy of SLIT for Japanese cedar pollinosis (JCP) using Japanese cedar (JC) pollen extract solution through a multicenter, placebo-controlled, double-blind comparative study. Based on its success in demonstrating the substantial efficacy of SLIT, we next conducted a larger-scale study by administering JC pollen to all JCP patients recruited. It was because of aiming to ascertain the effectiveness and safety of SLIT and its underlying mechanisms by comparing high- and non-responder patients. Despite limitations posed by liquid medication, significant effectiveness and safety demonstrated by the 2-year treatment served as the foundation for launching the first SLIT medicine for JCP, in 2014. Furthermore, in addition to the clearer Th1/Th2-imbalanced property in the high-responders, the possible involvement of bitter taste receptors in CD4⁺ T cells, apoptosis pathways in CD4⁺ T cells and basophils, and inducing a mast cell degranulation inhibitory molecule in the effect of SLIT was demonstrated. To solve the limitations posed by liquid medication, clinical trials evaluating JC pollen sublingual tablets started in 2014. Due to the minimal side effects, ease of administration, and convenient storage, the sublingual tablet medicine was launched in 2018. Giving the ongoing rise in demand for SLIT and considering that more than 1% of JCP patients are currently undergoing SLIT, the practical use of this treatment for multiple allergens is becoming increasingly important.</p></div>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"73 4","pages":"Pages 494-500"},"PeriodicalIF":6.2,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1323893024000741/pdfft?md5=f24fddb3028f69cc26157c962561bd3a&pid=1-s2.0-S1323893024000741-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141753125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A micropeptide TREMP encoded by lincR-PPP2R5C promotes Th2 cell differentiation by interacting with PYCR1 in allergic airway inflammation","authors":"Zhengxia Wang ,&nbsp;Xinyu Jia ,&nbsp;Wei Sun ,&nbsp;Min Wang ,&nbsp;Qi Yuan ,&nbsp;Tingting Xu ,&nbsp;Yanan Liu ,&nbsp;Zhongqi Chen ,&nbsp;Mao Huang ,&nbsp;Ningfei Ji ,&nbsp;Mingshun Zhang","doi":"10.1016/j.alit.2024.04.004","DOIUrl":"10.1016/j.alit.2024.04.004","url":null,"abstract":"<div><h3>Background</h3><p>Allergic asthma is largely dominated by Th2 lymphocytes. Micropeptides in Th2 cells and asthma remain unmasked. Here, we aimed to demonstrate a micropeptide, T-cell regulatory micropeptide (TREMP), in Th2 cell differentiation in asthma.</p></div><div><h3>Methods</h3><p>TREMP translated from lincR-PPP2R5C was validated using Western blotting and mass spectrometry. TREMP knockout mice were generated using CRISPR/Cas9. Coimmunoprecipitation revealed that TREMP targeted pyrroline-5-carboxylate reductase 1 (PYCR1), which was further explored <em>in vitro</em> and <em>in vivo</em>. The levels of TREMP and PYCR1 in Th2 cells from clinical samples were determined by flow cytometry.</p></div><div><h3>Results</h3><p>TREMP, encoded by lincR-PPP2R5C, was in the mitochondrion. The lentivirus encoding TREMP promoted Th2 cell differentiation. In contrast, Th2 differentiation was suppressed in TREMP^−/− CD4⁺ T cells. In the HDM-induced model of allergic airway inflammation, TREMP was increased in pulmonary tissues. Allergic airway inflammation was relieved in TREMP^−/− mice treated with HDM. Mechanistically, TREMP interacted with PYCR1, which regulated Th2 differentiation via glycolysis. Glycolysis was decreased in Th2 cells from TREMP^−/− mice and PYCR1^−/− mice. Similar to TREMP^−/− mice, allergic airway inflammation was mitigated in HDM-challenged PYCR1^−/− mice. Moreover, we measured TREMP and PYCR1 in asthma patients. And we found that, compared with those in healthy controls, the levels of TREMP and PYCR1 in Th2 cells were significantly increased in asthmatic patients.</p></div><div><h3>Conclusions</h3><p>The micropeptide TREMP encoded by lincR-PPP2R5C promoted Th2 differentiation in allergic airway inflammation by interacting with PYCR1 and enhancing glycolysis. Our findings highlight the importance of neglected micropeptides from noncoding RNAs in allergic diseases.</p></div>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"73 4","pages":"Pages 587-602"},"PeriodicalIF":6.2,"publicationDate":"2024-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1323893024000480/pdfft?md5=629e6caece9430e917d9d7ad68bdb5c6&pid=1-s2.0-S1323893024000480-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141724732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mucus plugging on computed tomography and the sputum microbiome in patients with asthma, chronic obstructive pulmonary disease, and asthma-COPD overlap","authors":"Naoya Tanabe ,&nbsp;Hisako Matsumoto ,&nbsp;Chie Morimoto ,&nbsp;Yusuke Hayashi ,&nbsp;Ryo Sakamoto ,&nbsp;Tsuyoshi Oguma ,&nbsp;Tadao Nagasaki ,&nbsp;Hironobu Sunadome ,&nbsp;Atsuyasu Sato ,&nbsp;Susumu Sato ,&nbsp;Kai Ohashi ,&nbsp;Takamitsu Tsukahara ,&nbsp;Toyohiro Hirai","doi":"10.1016/j.alit.2024.05.004","DOIUrl":"10.1016/j.alit.2024.05.004","url":null,"abstract":"<div><h3>Background</h3><p>Despite clinical implications, the pathogenesis of mucus plugging in asthma, chronic obstructive pulmonary disease (COPD), and asthma-COPD overlap (ACO) remains unclear. We hypothesized that distinct airway microbiomes might affect mucus plugging differently among ACO, asthma, and COPD and among different extents of airway eosinophilic inflammation.</p></div><div><h3>Methods</h3><p>The sputum microbiome, sputum cell differential count, and mucus plug score on computed tomography were cross-sectionally evaluated in patients with chronic airflow limitation.</p></div><div><h3>Results</h3><p>Patients with ACO, asthma, or COPD were enrolled (n = 56, 10, and 25). Higher mucus plug scores were associated with a greater relative abundance of the phylum Proteobacteria (rho = 0.29) only in patients with ACO and a greater relative abundance of the phylum Actinobacteria (rho = 0.46) only in patients with COPD. In multivariable models including only patients with ACO, the presence of mucus plugs was associated with a greater relative abundance of the phylum Proteobacteria and the genus <em>Haemophilus,</em> independent of smoking status, airflow limitation, and emphysema severity. Moreover, the mucus score was associated with a greater relative abundance of the genus <em>Streptococcus</em> (rho = 0.46) in patients with a high sputum eosinophil count (n = 22) and with that of the genus <em>Haemophilus</em> (rho = 0.46) in those with a moderate sputum eosinophil count (n = 26).</p></div><div><h3>Conclusions</h3><p>The associations between mucus plugging and the microbiome in ACO differed from those in COPD and asthma. Greater relative abundances of the phylum Proteobacteria and genus <em>Haemophilus</em> may be involved in mucus plugging in patients with ACO and moderate airway eosinophilic inflammation.</p></div>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"73 4","pages":"Pages 515-523"},"PeriodicalIF":6.2,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1323893024000558/pdfft?md5=114544772f389df010b7a70fa3790a50&pid=1-s2.0-S1323893024000558-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141628120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Age-related differences in olfactory profiles and surgical outcomes in eosinophilic chronic rhinosinusitis","authors":"Kosuke Akiyama ,&nbsp;Yukako Arakawa ,&nbsp;Yasushi Samukawa ,&nbsp;Hiroshi Hoshikawa","doi":"10.1016/j.alit.2024.05.003","DOIUrl":"10.1016/j.alit.2024.05.003","url":null,"abstract":"","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"73 4","pages":"Pages 607-609"},"PeriodicalIF":6.2,"publicationDate":"2024-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1323893024000546/pdfft?md5=6376877fea11bae495ab8e028fe27e3f&pid=1-s2.0-S1323893024000546-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141617434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Allergen immunotherapy in asthma","authors":"","doi":"10.1016/j.alit.2024.05.005","DOIUrl":"10.1016/j.alit.2024.05.005","url":null,"abstract":"<div><p>Allergen immunotherapy (AIT), including SCIT and SLIT, is a treatment that involves the administration of allergens to which patients with allergic diseases have been sensitized. HDM-SCIT for asthma is indicated in cases of HDM-sensitized allergic asthma with normal lung function. HDM-SCIT improves asthma symptoms and AHR, and decreases the medication dose. Importantly, AIT can improve other allergic diseases complicated by asthma, such as allergic rhinitis, which can also contribute to the improvement of asthma symptoms. Several studies have suggested that HDM-SLIT also attenuates the risk of asthma exacerbations, and improves lung function in asthma cases with allergic rhinitis. Furthermore, AIT can modify the natural course of allergic diseases, including asthma. For example, the effects of AIT are maintained for at least several years after treatment discontinuation. AIT can prevent the onset of asthma when introduced in allergic rhinitis, and can also inhibit or reduce new allergen sensitizations. Recent data have suggested that AIT may suppress non-targeted allergen-induced immune responses in addition to targeted allergen-induced responses, and suppress infections of the lower respiratory tract by enhancing IFN responses.</p></div>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"73 4","pages":"Pages 487-493"},"PeriodicalIF":6.2,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S132389302400056X/pdfft?md5=111d276e9163c087baa89fee53a87a63&pid=1-s2.0-S132389302400056X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141493999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of very-low-dose oral food challenge in children with severe hen egg allergy: A retrospective, single-center case series","authors":"","doi":"10.1016/j.alit.2024.05.006","DOIUrl":"10.1016/j.alit.2024.05.006","url":null,"abstract":"<div><h3>Background</h3><p>To avoid complete elimination of hen eggs (HE) from diet, we introduced a very-low-dose (VLD) oral food challenge (OFC) in patients with severe HE allergy in 2019. Herein, we investigated the efficacy of VLD HE OFC for achieving the full dose OFC.</p></div><div><h3>Methods</h3><p>Patients with an overt allergic reaction to LD (1/32 HE [≤100 mg]) or less, egg white (EW) protein within 6 months were included. In the VLD group, patients not achieving full-dose OFC (1/2 HE: 1600 mg EW protein) within 2 years were excluded. We retrospectively compared the rate of passing a full-dose OFC between patients who underwent a LD OFC before 2019 (LD group) and those who underwent a VLD OFC (1/100 HE: 32 mg EW protein) after 2019 (VLD group). The period for passing the full-dose OFC was evaluated using Kaplan–Meier survival analysis.</p></div><div><h3>Results</h3><p>We enrolled 411 and 111 patients in the LD and VLD groups, respectively. The median age at OFC initiation was 2.2 [1.5–3.6] and 2.1 [1.4–3.2] years in the LD and VLD groups, respectively. EW- and ovomucoid-specific IgE levels were 38.3 (12.5–72.9) and 21.0 (8.3–46.2) kU_A/L in the LD group and 49.8 [18.8–83.9] and 32.1 [15.6–67.8] kU_A/L in the VLD group, respectively. Over 4 years, the LD and VLD groups passed the full-dose OFC at rates of 70 and 95%, respectively, with significant differences (log-rank test, <em>P</em> &lt; 0.001).</p></div><div><h3>Conclusions</h3><p>VLD HE OFC may contribute to passing a full-dose OFC in patients with severe HE allergies.</p></div>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"73 4","pages":"Pages 543-549"},"PeriodicalIF":6.2,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1323893024000728/pdfft?md5=044f126a4253d56df28e62e8e2dbc291&pid=1-s2.0-S1323893024000728-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141437624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mucus plugs in severe asthma and related airway diseases","authors":"Koichiro Asano Associate Editor, Allergology International","doi":"10.1016/j.alit.2024.06.001","DOIUrl":"https://doi.org/10.1016/j.alit.2024.06.001","url":null,"abstract":"","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"73 3","pages":"Pages 349-350"},"PeriodicalIF":6.8,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1323893024000571/pdfft?md5=08e72cc8d310f7e5f55ba934956b9b73&pid=1-s2.0-S1323893024000571-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141429791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}